Skip to content
MARKETS / OWPC
PHARMACEUTICAL PREPARATIONS · SMALL CAP

One World Products, Inc. OWPC

10 fiscal years on record · USD · FY2024 reported · SEC filings only
$4,863
▼ 35.9% YoY
$-3.9M
In brief

What this company does

As a result of the Merger, we are engaged in OWP Ventures’ business, including the business of its wholly-owned subsidiary, One World Pharma, S.A.S., a Colombian company (“OWP SAS”). During March of 2024, the Company, through OWP Ventures, began to sell a CBD based product in the United States, called Pro-11. The Company is developing its industrial hemp solutions business targeting the automotive market. In October of 2024, the Company, in collaboration with partners in the automotive industry, developed hemp-based molded containers for automotive part packaging applications and received an initial order for 1,400 units of these reusable totes, designed to move and protect automotive parts through the supply chain. Our business currently involves the sale of CBD based product in the United States, called Pro-11. Our primary active business operations are currently the sale of cannabidiol (CBD) products derived from hemp.

Written from the business description in One World Products, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 3 June 2025. Every sentence was checked against that document before publication.

Growth
USD 4,863.00
Revenue, FY2024 · full 10-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.0 · Net income -3.9
-4M2015201620172018201920202021202220232024
Compound annual growth
−49.7%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−80917 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -38494.6% · Net -80917.4%
-50000%2015201620172018201920202021202220232024
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Gross margin80.5%
Operating margin-38494.6%
Net margin-80917.4%
Return on assets-4707.5%
EBITDAUSD -1.9M

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -1.2
-2M-4M2015201620172018201920202021202220232024

Total assetsUSD 68,300.00
EquityUSD -9.9M
Current ratio0.02×

Equity funds -14512% of total assets.

The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2024202320222021202020192018201720162015
Revenue $B0.00.00.00.00.0·····
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0····
Income tax $B··········
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B·−0.0−0.0−0.0−0.0−0.0····
EPS, diluted $−0.04−0.05−0.05−0.06−0.20−0.15−0.02−0.040.000.00
Dividend / sh $0.000.000.000.000.000.00····
Payout %··········
ROE %··········
Shares out B0.110.080.070.070.050.040.030.000.010.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 39 reconciliationsAUDITED

Reconciled in 10 of 19 fiscal years. 56 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onnot stated in the filings
Incorporated inNevada
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2015

Share this section

Download image